cancer Archives - Pharmaphorum

What HCPs say about Roche’s breast cancer drug

July 17, 2017

The online conversations about breast cancer drug Kadcyla before it was approved by NICE.

What HCPs say about Roche’s breast cancer drug

https://pharmaphorum.com/views-and-analysis/roche-breast-cancer-drug/

Biosimilars manufacturers close in on Roche cancer blockbusters

July 14, 2017

FDA panel backs Herceptin and Avastin biosimilars.

Biosimilars manufacturers close in on Roche cancer blockbusters

https://pharmaphorum.com/news/biosimilars-herceptin/

Microbiome: Translating into Diagnostics and BioTherapeutics

July 14, 2017

Emerging technologies in Microbiome discovery

Microbiome: Translating into Diagnostics and BioTherapeutics

https://pharmaphorum.com/events/microbiome-translating-into-diagnostics-and-biotherapeutics-summit/

IBM Watson impresses in brain tumour analysis

July 13, 2017

Watson for Genomics produces treatment insights for glioblastoma in 10 minutes.

IBM Watson impresses in brain tumour analysis

https://pharmaphorum.com/news/watson-for-genomics-brain-tumour/

AZ CEO set to take charge at Teva – report

July 13, 2017

Report raises concerns about outcome of MYSTIC trial.

AZ CEO set to take charge at Teva – report

https://pharmaphorum.com/news/az-ceo-teva/

Novartis close to first-ever CAR-T approval after unanimous vote

July 13, 2017

Panel unanimously back CTL019

Novartis close to first-ever CAR-T approval after unanimous vote

https://pharmaphorum.com/news/novartis-car-t-ctl019-backed-fda-advisers/

Mylan/Biocon Herceptin biosimilar faces EU delay

July 12, 2017

EU inspectors require re-inspection of Bangalore plant.

Mylan/Biocon Herceptin biosimilar faces EU delay

https://pharmaphorum.com/news/mylanbiocon-herceptin-biosimilar-faces-eu-delay/

The curious case of Mylotarg: Pfizer’s leukaemia drug set to return

July 12, 2017

Mylotarg backed by advisers after withdrawal in 2010.

The curious case of Mylotarg: Pfizer’s leukaemia drug set to return

https://pharmaphorum.com/news/pfizer-mylotarg-looks-set-return/

Novartis CAR-T safety in FDA spotlight

July 11, 2017

FDA advisers are set to make recommendations on Novartis’ groundbreaking CAR-T therapy CTL019 tomorrow – and are set to

Novartis CAR-T safety in FDA spotlight

https://pharmaphorum.com/news/fda-advisers-consider-novartis-car-t-safety/

Trending

cancer

Biosimilars manufacturers close in on Roche cancer blockbusters

Microbiome: Translating into Diagnostics and BioTherapeutics

AZ CEO set to take charge at Teva – report

Novartis close to first-ever CAR-T approval after unanimous vote

Mylan/Biocon Herceptin biosimilar faces EU delay

The curious case of Mylotarg: Pfizer’s leukaemia drug set to return

Novartis CAR-T safety in FDA spotlight

Partnerships in Clinical Trials Europe | 28-29 November 2017 | RAI, Amsterdam

Inhalation and Respiratory Drug Products Summit

THET Annual Conference 2017

RA pill setback spoils Lilly’s growth story

Celgene hopes device + drug can tackle aggressive brain tumours

Tocagen’s brain tumour candidate gets PRIME designation

NHS should pay for medicines based on outcomes, argues Novartis-backed report

Amazon looks set to enter healthcare market

Managing chronic illness in children and adolescents

Health literacy ‘elephant in the room’ in patient engagement

The most notable digital health trends of 2017 so far

Europe has untapped medical innovation – but needs high speed connections to make it work

Healthcare’s hype cycle: which technologies will stay the course?

Search

Advanced Search

Trending

cancer